Age-related diseases (ARDs)

The first set of speakers for Rejuvenation Startup Summit 2024 (Berlin, 10-11 May 2024) has been announced. The networking event aims to bring together startups and members of the longevity venture capital/investor ecosystem to create therapies to vastly extend the healthy human lifespan. In addition to presentations from CEOs of startups in the fields of […]

Longevity biotech clock.bio has launched with $4 million in funding to develop regenerative medicines to prevent and treat age-related diseases. The company says its immediate objective is to decode all rejuvenation programmes present in human cells, to build an atlas of disease and rejuvenation targets for clinical translation. “We have a bold mission of extending […]

Three drugs that could help stave off the effects of ageing have been discovered using artificial intelligence (AI), a study by Edinburgh researchers suggests. Findings suggest the drugs can safely remove defective cells – known as senescent cells – linked to conditions including cancer, Alzheimer’s disease and declines in eyesight and mobility. While previous studies […]

This is the latest episode of the free DDW narrated podcast, “The impact of technology on drug discovery”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Talking Tech” and “Rejuvenation biotech: Can this company make age a thing of the past?” With Covid-19 taking so […]

New data suggest that AKL Therapeutics’ investigational oral osteoarthritis (OA) drug APPA may have a dual effect on age-related cellular senescence. Senescence, a process in which cells stop dividing, plays a major role in the development of many age-related diseases, including OA. The study, using a human chondrocyte (cartilage-forming) cell line, was carried out at […]

Five Alarm Bio (FAB) has completed a seed investment round, raising over £500K ($605K). The funding will drive proprietary research into novel compounds that extend healthy lifespan of cells and tissues, with therapeutic potential across a broad range of age-related diseases. Investors include Cambridge Angels, Meltwind, o2h Ventures, and SyndicateRoom, as well as other Angel […]

A new study has demonstrated the ability of an experimental regenerative medicine to restore bone in an animal.  Bone loss is a part of ageing that compromises quality of life and movement in many older people, but regenerative treatments to improve their health and well-being have been limited.  The preclinical study, led by Lankenau Institute […]

A new report reveals steadily growing interest in the clinical applications of collagen over the last 10 years.  Data analytics company Phesi analysed 2,358 clinical trials involving collagen. In the first 10 months of 2022, there were more than 225 new trials, compared with 125 in 2012. Dr Gen Li, CEO and Founder, Phesi, said: […]

Listen to this article on the DDW Podcast: Kizoo Technology Capital has a clear aim – to develop drugs that abate or cure age-related diseases. Lu Rahman spoke to owner, Michael Greve to find out more about this exciting work that aims to make age-related therapies affordable for everyone. Kizoo is investing €300 million in a […]